1
|
Cheng X, Pan R, Tang J, Yu K, Zhang H, Zhao X. Preliminary Study on Pharmacokinetics and Antitumor Pharmacodynamics of Folic Acid Modified Crebanine Polyethyleneglycol-Polylactic Acid Hydroxyacetic Acid Copolymer Nanoparticles. Int J Nanomedicine 2024; 19:10513-10536. [PMID: 39435040 PMCID: PMC11492913 DOI: 10.2147/ijn.s477027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2024] [Accepted: 10/09/2024] [Indexed: 10/23/2024] Open
Abstract
Purpose Liver cancer is associated significantly with morbidity and mortality. The combination of low-intensity ultrasound with nanomedicine delivery systems holds promise as an alternative for the treatment for liver cancer. This study focuses on the utilization of folic acid (FA) modified nanoparticles, which are loaded with fluorescent dye DiR and liquid fluorocarbon (PFP). These nanoparticles have the potential to enhance liver cancer targeting under ultrasound stimulation and future applications in vivo. Methods The pharmacokinetics and tissue distribution of folic acid-modified Crebanine polyethylene glycol-polylactic acid copolymer nanoparticles (FA-Cre@PEG-PLGA NPs) were investigated. The pharmacokinetic parameters, liver targeting, and in vivo distribution were assessed. Additionally, the inhibitory impacts of FA-Cre@PEG-PLGA NPs in combination with ultrasonic irradiation on the proliferation and acute toxicity of H22 cells of mouse hepatoma were investigated in vitro. The tumor targeting and anti-tumor efficacy of FA-Cre@PEG-PLGA NPs were assessed utilizing a small animal in vivo imaging system and an in situ hepatocellular carcinoma transplantation model, respectively. Results The pharmacokinetic studies and tissue distribution tests demonstrated that FA-Cre@PEG-PLGA NPs conspicuously prolonged the half-life and retention time of the drug in rats, and the liver targeting effect was pronounced. Additionally, the in vivo acute toxicity test indicated that FA-Cre@PEG-PLGA NPs had minimal adverse reactions and could fulfill the aim of attenuating the drug. The outcomes of the animal experiments further substantiated that FA-Cre@PEG-PLGA NPs had a longer retention time at the tumor site, a superior anti-tumor effect, and less damage to liver and kidney tissue. Conclusion The integration of FA-Cre@PEG-PLGA NPs with ultrasound irradiation demonstrated exceptional safety and potent anti-tumor efficacy in vivo, presenting a promising therapeutic strategy for the treatment of liver cancer through the combination of ultrasound technology with a nanomedicine delivery system.
Collapse
Affiliation(s)
- Xin Cheng
- College of Traditional Chinese Medicine, Yunnan University of Chinese Medicine, Kunming, 650500, People’s Republic of China
- The Key Laboratory of External Drug Delivery System and Preparation Technology in University of Yunnan Province, Kunming, 650500, People’s Republic of China
- Yunnan Key Laboratory of Dai and Yi Medicines, Kunming, 650500, People’s Republic of China
- Laboratory Animal Center, Yunnan University of Chinese Medicine, Kunming, 650500, People’s Republic of China
| | - Rui Pan
- College of Traditional Chinese Medicine, Yunnan University of Chinese Medicine, Kunming, 650500, People’s Republic of China
- Yunnan Key Laboratory of Dai and Yi Medicines, Kunming, 650500, People’s Republic of China
- Laboratory Animal Center, Yunnan University of Chinese Medicine, Kunming, 650500, People’s Republic of China
- College of Chinese Materia Medica and Yunnan Key Laboratory of Southern Medicinal Utilization, Kunming, 650500, People’s Republic of China
| | - Junze Tang
- College of Traditional Chinese Medicine, Yunnan University of Chinese Medicine, Kunming, 650500, People’s Republic of China
- Laboratory Animal Center, Yunnan University of Chinese Medicine, Kunming, 650500, People’s Republic of China
| | - Kun Yu
- College of Traditional Chinese Medicine, Yunnan University of Chinese Medicine, Kunming, 650500, People’s Republic of China
- Laboratory Animal Center, Yunnan University of Chinese Medicine, Kunming, 650500, People’s Republic of China
| | - Hailiang Zhang
- College of Traditional Chinese Medicine, Yunnan University of Chinese Medicine, Kunming, 650500, People’s Republic of China
- Yunnan Key Laboratory of Dai and Yi Medicines, Kunming, 650500, People’s Republic of China
- Laboratory Animal Center, Yunnan University of Chinese Medicine, Kunming, 650500, People’s Republic of China
- College of Chinese Materia Medica and Yunnan Key Laboratory of Southern Medicinal Utilization, Kunming, 650500, People’s Republic of China
| | - Xiaoyu Zhao
- College of Traditional Chinese Medicine, Yunnan University of Chinese Medicine, Kunming, 650500, People’s Republic of China
- Laboratory Animal Center, Yunnan University of Chinese Medicine, Kunming, 650500, People’s Republic of China
| |
Collapse
|
2
|
Alavi SE, Alharthi S, Alavi SZ, Raza A, Ebrahimi Shahmabadi H. Bioresponsive drug delivery systems. Drug Discov Today 2024; 29:103849. [PMID: 38052319 DOI: 10.1016/j.drudis.2023.103849] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Revised: 11/26/2023] [Accepted: 11/29/2023] [Indexed: 12/07/2023]
Abstract
In this review, we highlight the potential of stimuli-responsive drug delivery systems (DDSs) to revolutionize healthcare. Through examining pH, temperature, enzyme, and redox responsiveness, the presented case studies highlight the precision and enhanced therapeutic outcomes achievable with these innovative systems. Challenges, such as complex design and bio-based material optimization, underscore the complete journey from bench to bedside. Clinical strides in magnetically and temperature-responsive systems hint at a promising future for healthcare. However, overcoming issues of stability, durability, penetration depth, sensitivity, and active targeting is crucial. The future envisions theranostic systems, amalgamating targeted therapy and diagnosis, for personalized healthcare. Bio-based materials emerge as pivotal, offering a nuanced approach to complex diseases, such as cancer and diabetes, reshaping the healthcare landscape.
Collapse
Affiliation(s)
- Seyed Ebrahim Alavi
- Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan 7718175911, Iran.
| | - Sitah Alharthi
- Department of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, Al-Dawadmi Campus, Al-Dawadmi 11961, Saudi Arabia
| | - Seyed Zeinab Alavi
- Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan 7718175911, Iran
| | - Aun Raza
- School of Pharmacy, Fudan University, Shanghai 201203, PR China
| | - Hasan Ebrahimi Shahmabadi
- Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan 7718175911, Iran.
| |
Collapse
|
3
|
Sharma R, Shrivastava P, Gautam L, Agrawal U, Mohana Lakshmi S, Vyas SP. Rationally designed block copolymer-based nanoarchitectures: An emerging paradigm for effective drug delivery. Drug Discov Today 2023; 28:103786. [PMID: 37742910 DOI: 10.1016/j.drudis.2023.103786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2023] [Revised: 09/05/2023] [Accepted: 09/19/2023] [Indexed: 09/26/2023]
Abstract
Various polymeric materials have been investigated to produce unique modes of delivery for drug modules to achieve either temporal or spatial control of bioactives delivery. However, after intravenous administration, phagocytic cells quickly remove these nanostructures from the systemic circulation via the reticuloendothelial system (RES). To overcome these concerns, ecofriendly block copolymers are increasingly being investigated as innovative carriers for the delivery of bioactives. In this review, we discuss the design, fabrication techniques, and recent advances in the development of block copolymers and their applications as drug carrier systems to improve the physicochemical and pharmacological attributes of bioactives.
Collapse
Affiliation(s)
- Rajeev Sharma
- Amity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior, MP 474005, India
| | - Priya Shrivastava
- Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr Harisingh Gour Central University, Sagar, MP 470003, India
| | - Laxmikant Gautam
- Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr Harisingh Gour Central University, Sagar, MP 470003, India; Babulal Tarabai Institute of Pharmaceutical Science, Sagar, M.P., 470228
| | - Udita Agrawal
- Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr Harisingh Gour Central University, Sagar, MP 470003, India
| | - S Mohana Lakshmi
- Amity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior, MP 474005, India
| | - Suresh P Vyas
- Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr Harisingh Gour Central University, Sagar, MP 470003, India.
| |
Collapse
|
4
|
Ma P, Huang J, Liu J, Zhu Y, Chen J, Chen J, Lei L, Guan Z, Ban J, Lu Z. Nanoformulation of Paclitaxel: Exploring the Cyclodextrin / PLGA Nano Delivery Carrier to Slow Down Paclitaxel Release, Enhance Accumulation in Vivo. J Cancer 2023; 14:759-769. [PMID: 37056390 PMCID: PMC10088884 DOI: 10.7150/jca.82410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Accepted: 03/03/2023] [Indexed: 04/15/2023] Open
Abstract
Background: Improving the aggregation and penetration in tumor sites increases the anti-tumor efficacy of nanomedicine. In the current study, we designed cyclodextrin modified PLGA nanoparticles loaded with paclitaxel to elevate the accumulation and prolong circulation of chemotherapy drugs in vivo. Methods: The PLGA nanoparticles loaded with paclitaxel (PTX PLGA NPs) and cyclodextrin (CD) modified PLGA nanoparticles loaded with paclitaxel (PTX PLGA/CD NPs) were prepared using the emulsification solvent evaporation method. The nanoparticles were characterized by particle size, zeta potential, encapsulation efficiency, infrared spectroscopy analysis and X-Ray diffraction (XRD). Then, drug release of the nanoparticles was evaluated via reverse dialysis method in vitro. Finally, the in vivo distribution fate and pharmacokinetic characteristics of the nanoparticles were assessed in mice and rats. Results: The average particle size, zeta potential, and encapsulation efficiency of PTX PLGA NPs were (163.57±2.07) nm, - (20.53±2.79) mV and (60.44±6.80)%. The average particle size, zeta potential, and encapsulation efficiency of PTX PLGA/CD NPs were (148.57±1.66) nm, - (11.42±0.84) mV and (85.70±2.06)%. In vitro release studies showed that PTX PLGA/CD NPs were released more slowly compared to PTX PLGA NPs under normal blood pH conditions, while PTX PLGA/CD NPs were released more completely under tumor site pH conditions. The modified PLGA nanocarrier (PLGA/CD NPs) increased drug residence time and accumulation than the plain PLGA nanocarrier (PLGA NPs) in vivo distribution. In addition, the elimination half-life, area under the drug-time curve, and maximum blood concentration of the nanoparticle group were higher than those of Taxol®, especially the PTX PLGA/CD NPs group, which was significantly different from Taxol® and plain nanoparticle groups (p<0.001). Conclusions: The 2-HP-β-CD modified PLGA nanoparticles prolonged circulation time and accumulation of the chemotherapy drug paclitaxel in vivo.
Collapse
Affiliation(s)
- Peilin Ma
- Guangdong Pharmaceutical University, Guangzhou, People's Republic of China
| | - JiaYing Huang
- Guangdong Pharmaceutical University, Guangzhou, People's Republic of China
| | - Jinling Liu
- Guangdong Pharmaceutical University, Guangzhou, People's Republic of China
| | - Yi Zhu
- Guangdong Pharmaceutical University, Guangzhou, People's Republic of China
- The Innovation Team for Integrating Pharmacy with Entrepreneurship, Guangdong Pharmaceutical University, Guangzhou, People's Republic of China
| | - Jiahong Chen
- Guangdong Pharmaceutical University, Guangzhou, People's Republic of China
- The Innovation Team for Integrating Pharmacy with Entrepreneurship, Guangdong Pharmaceutical University, Guangzhou, People's Republic of China
| | - Junming Chen
- Guangdong Pharmaceutical University, Guangzhou, People's Republic of China
- The Innovation Team for Integrating Pharmacy with Entrepreneurship, Guangdong Pharmaceutical University, Guangzhou, People's Republic of China
| | - Lunwen Lei
- The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, People's Republic of China
| | - Ziyun Guan
- The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, People's Republic of China
| | - Junfeng Ban
- Guangdong Pharmaceutical University, Guangzhou, People's Republic of China
- The Innovation Team for Integrating Pharmacy with Entrepreneurship, Guangdong Pharmaceutical University, Guangzhou, People's Republic of China
- Guangdong Provincial Key Laboratory of Advanced Drug Delivery Systems, Guangdong Pharmaceutical University, Guangzhou, People's Republic of China
- Guangdong Provincial Engineering Center of Topical Precision Drug Delivery System, Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou, People's Republic of China
- ✉ Corresponding authors: Dr. Ban Junfeng.
| | - Zhufen Lu
- Guangdong Pharmaceutical University, Guangzhou, People's Republic of China
- The Innovation Team for Integrating Pharmacy with Entrepreneurship, Guangdong Pharmaceutical University, Guangzhou, People's Republic of China
- Guangdong Provincial Key Laboratory of Advanced Drug Delivery Systems, Guangdong Pharmaceutical University, Guangzhou, People's Republic of China
- ✉ Corresponding authors: Dr. Ban Junfeng.
| |
Collapse
|